Brief: Nkgen Biotech Says It Entered Into Amendment To Forward Purchase Agreement, Dated As Of Sept 26, 2023
22/01/2024 12:05
Jan 22 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH - ON JAN 19, CO & SELLER ENTERED INTO
AMENDMENT TO
FORWARD PURCHASE AGREEMENT, DATED AS OF SEPT 26, 2023
* NKGEN BIOTECH - PURSUANT TO AMENDMENT, CO AND SELLERS
AGREED TO
AGGREGATE AMOUNT OF SHORTFALL SALES TO EQUATE TO 120% OF FUTURE
SHORTFALL
* NKGEN BIOTECH - PURSUANT TO AMENDMENT, CO AND SELLERS
AGREED
INCREASE PREPAYMENT SHORTFALL BY $250,000
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program